Back to Search
Start Over
B7-H3 Inhibitors in Oncology Clinical Trials: A Review.
- Source :
-
Journal of Immunotherapy & Precision Oncology . Feb2024, Vol. 7 Issue 1, p53-66. 14p. - Publication Year :
- 2024
-
Abstract
- B7-H3 is a transmembrane receptor highly prevalent on malignant cells and plays an important role in adaptive immunity that is not fully elucidated. Targeted B7-H3 inhibitors, including antibody-drug conjugates, radioimmunotherapy, and monoclonal antibodies, are a new class of antineoplastic agents showing promising preliminary clinical efficacy, observed with several of these agents against multiple tumor types. Particularly promising treatments are enoblituzumab for prostate cancer, 131Iomburtamab for central nervous system malignancies, and HS-20093 for small-cell lung cancer but further studies are warranted. There are clinical trials on the horizon that have not yet enrolled patients examining chimeric antigen receptor Tcell therapies, bi- and tri-specific killer engagers, and dual-affinity retargeting proteins. These data will be telling of the efficacy of B7-H3 inhibitors in both hematologic and solid malignancies. This study aimed to compile available results of B7-H3 inhibitors in oncology clinical trials. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 26662345
- Volume :
- 7
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Journal of Immunotherapy & Precision Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 176029163
- Full Text :
- https://doi.org/10.36401/JIPO-23-18